Secukinumab/Adalimumab-Biosimilar
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Axial Spondyloarthritis
Conditions
Axial Spondyloarthritis
Trial Timeline
Jun 4, 2019 → Sep 22, 2022
NCT ID
NCT03906136About Secukinumab/Adalimumab-Biosimilar
Secukinumab/Adalimumab-Biosimilar is a phase 3 stage product being developed by Novartis for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03906136. Target conditions include Axial Spondyloarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03906136 | Phase 3 | Completed |
Competing Products
20 competing products in Axial Spondyloarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| Brodalumab + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Upadacitinib | AbbVie | Pre-clinical | 23 |
| Adalimumab | AbbVie | Approved | 85 |
| Adalimumab + Placebo + Open-label Adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Treatment | Merck | Pre-clinical | 23 |
| Golimumab | Merck | Phase 3 | 77 |
| Tulisokibart + Placebo | Merck | Phase 2 | 52 |
| Secukinumab 150 milligram [Cosentyx] | Novartis | Approved | 85 |
| secukinumab | Novartis | Pre-clinical | 23 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| Secukinumab + Placebo + Secukinumab | Novartis | Approved | 85 |
| Secukinumab + Secukinumab and Placebo | Novartis | Phase 3 | 77 |
| Brodalumab 210 mg + Placebo | Amgen | Phase 2 | 51 |
| Etanercept 25mg + Sulfasalazine | Pfizer | Phase 2 | 51 |